Cross Country Healthcare heads into tonight's Q1 2026 earnings release with options positioning markedly more bullish than usual — and with short sellers meaningfully backing away.
The options market is the clearest signal. The put/call ratio has dropped to 0.55, more than 2.4 standard deviations below its 20-day average of 0.68 — the most call-heavy reading of the past year. That's a sharp pivot from April, when the PCR hovered around 0.70. Traders have clearly rotated toward upside exposure rather than protection heading into the print. Borrow conditions confirm the lighter bearish footprint: the cost to borrow a modest 0.72% annually, and availability in the lending pool is wide — well away from any squeeze dynamics.
Short sellers have spent the past month unwinding positions at pace. SI has fallen more than 55% over 30 days, dropping from roughly 1.97 million shares in early April to under 885,000 — now just 2.7% of the free float. Days to cover ticks at around 5.3, which is not negligible for a small-cap name, but the direction of travel is unambiguously toward the exit. The stock closed Wednesday at $10.11, down 5.2% on the day but up 10% over the prior month — suggesting the April rally drew some profit-taking rather than a fresh wave of bearish conviction.
The analyst community tilted more constructive earlier in the year. In March, Wedbush upgraded CCRN to Outperform and raised its target to $15, while Benchmark moved to Buy with a $14 target — both following the Q4 print that sent shares up more than 10% in a single session. The consensus now blends five Hold ratings with two Outperforms, and the mean target implies roughly 9% upside from current levels. Bulls point to the pending Aya Healthcare acquisition at $18.61 per share — a 67% premium to pre-announcement prices — as a floor that anchors valuation. Bears counter with a bleak revenue trajectory: Q1 2025 revenue was down 23% year-over-year at $293 million, adjusted EBITDA collapsed 44%, and forward estimates have been revised steadily lower since. The estimated Q1 2026 revenue sits near $237 million — implying further contraction — and the EPS surprise factor ranks in just the 1st percentile, a warning that beat rates have been poor. EPS momentum over the last 90 days, however, ranks in the 96th percentile, suggesting estimates have been cut far enough to make the bar beatable.
Ownership has been broadly stable, with BlackRock and Vanguard among the top holders. Sio Capital Management and Quinn Opportunity Partners appear as new entrants in the December 2025 filings, each building positions of roughly 3% — a sign that at least some event-driven capital has accumulated in anticipation of the acquisition close. March insider activity was routine and small-scale, largely driven by tax-related sales.
Tonight's print is therefore less about organic revenue momentum and more about whether Cross Country can deliver enough margin stability to keep the Aya deal thesis intact — and whether management has any update on the acquisition timeline.
See the live data behind this article on ORTEX.
Open CCRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
